Comment from Biocom

Summary: Biocom, an advocacy organization representing California's life science sector, supports the FDA's proposed pilot program for AI-enabled optimization of early-phase clinical trials. They argue that the program should focus on specific therapeutic areas like oncology, maintain human oversight for all critical safety and regulatory decisions, and establish clear frameworks for data maturity, auditability, and risk-based validation.